Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Repotrectinib Highly Active in ROS1-positive Lung Cancer
Key clinical point: The oral TKI repotrectinib is safe and has demonstrated encouraging activity in patients with advanced ROS1 fusion-positive NSCLC.
Major finding: Objective response rates were 82% in TKI-naive patients and 39% in TKI-pretreated patients.
Study details: Preliminary results of a phase 1/2 study including 11 patients with TKI-naive disease and 22 previously treated patients.
Disclosures: Turning Point Therapeutics sponsored the study. Dr. Cho reported disclosures related to TheraCanVac, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Champions Oncology, Dizal Pharma, Dong-A ST, Eli Lilly, Janssen, Mogam Institute, MSD, Novartis, Ono, Pfizer, Roche, Takeda, and Yuhan.
Cho BC et al. ASCO 2019, Abstract 9011.